Vertex Pharmaceuticals upgraded to "outperform"

02/01/10 - Oppenheimer

NEW YORK, February 1 (newratings.com) - Analysts at Oppenheimer & Co upgrade Vertex Pharmaceuticals Incorporated (VRTX) from "perform" to "outperform." The target price is set to $47.